TickerTalks
Browse all tickers →
TickerTalks›$DFTX
DFDFTX

Definium Therapeutics, Inc.

$DFTX·$4.8B·Biotechnology·Healthcare
$44.29+0.4%YTD+228.1%1Y+398.8%
Mentions · last 7 days
2026-07-12: 11 posts2026-07-13: 53 posts2026-07-14: 50 posts2026-07-15: 71 posts2026-07-16: 117 posts2026-07-17: 57 posts2026-07-18: 1 posts367+15%
Price updated 2d ago·X counts updated 1h ago
DFDFTX
$DFTXDefinium Therapeutics, Inc.
$44.29+0.43%367 posts+15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DFTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeAcceleratingAI verdict · as of 2026-07-19

The move is getting stronger, with heavier trading behind it.

Psychedelic biotech up 228% YTD after Lilly-ATAI acquisition validated the space — Phase 3 program is the specific catalyst.

Definium Therapeutics is a mid-cap psychedelics-focused biotech with a more advanced Phase 3 program for generalized anxiety disorder (GAD). Up 228% YTD and 399% over 12 months as the Lilly-ATAI acquisition has re-rated the whole psychedelic sector — sitting at 88% of the 52-week range.

  • The Lilly-ATAI acquisition is the specific sector-rerating catalyst: ATAI Life Sciences was acquired by Eli Lilly at a substantial premium, validating psychedelics as a real pharma-buying target — bulls (rightly) note DFTX with its more advanced Phase 3 program in GAD is a natural next takeout candidate, and Wall Street analysts see a 32% average upside.
  • The financials are entirely pre-commercial: revenue is $0, operating margins undefined, and consensus FY26 EPS of -$2.22 improving to -$1.60 in FY27 shows the sell side models continued burn — the equity is priced entirely on probability-weighted GAD Phase 3 success + takeout probability, both of which are legitimately elevated post-ATAI.
  • Recent dilution + insider selling adds a caution note: the June 23 offering of 20.6M shares at $34 (below the $36.18 prior close) raised roughly $700M but signals management prioritized cash-runway over pricing, and $2.6M of insider selling on June 26 (Sullivan, Wiley, Roberts) into the run is the exact pattern of executive de-risking that often follows a large capital raise.

The July 30 earnings print is where either fresh Wired for Worry (GAD initiative) commentary combined with any Phase 3 timeline update restarts the setup toward $60+, or a soft strategic-update combined with continued psychedelic-sector digestion pushes the stock back below $35. Real sector re-rating with a specific pipeline catalyst — the print has to sustain the ramp.

Agrees with X sentimentX is confidently bullish accumulation on the Lilly-ATAI sector re-rating with DFTX as the natural next takeout candidate, and the mechanics fully back that framing — the ATAI deal validation is real and DFTX has a genuine Phase 3 program in GAD. The counter is the $700M raise + insider selling into the run, which is the pattern that often follows a large placement.

What to watch: July 30 earnings — fresh Wired for Worry commentary combined with any Phase 3 timeline update restarts the setup toward $60+; a soft strategic-update combined with continued psychedelic-sector digestion pushes the stock back below $35.

On the calendar: 2026-07-30 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment15 posts analyzed · as of 2026-07-18

Definium Therapeutics ($DFTX) is riding the Lilly-ATAI acquisition tailwind, crossing $50-plus in after-hours trading (above 52-week high) as psychedelic re-rating accelerates. Bulls emphasize the $ATAI buyout is further validation of the psychedelic thesis and expect DFTX (with its more advanced Phase 3 program) to be next. Bears note the market may turn short-term bearish on psychedelics as it digests the ATAI deal. Overall tone is confidently bullish accumulation on the sector re-rating catalyst.

Read the AI verdict + X sentiment for $DFTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing psychedelic-based therapies (synthetic LSD derivative MM120) for anxiety and ADHD.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DFTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $DFTX

Partial — Clinical-stage biotech developing psychedelic-based therapies (synthetic LSD derivative MM120) for anxiety and ADHD; exposure exists but is diluted by diverse end markets and revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-10.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-102%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.71$-0.47-51.1%
Q4 2025Feb 26, 2026$-0.51$-0.48-5.4%
Q3 2025Nov 6, 2025$-0.78$-0.52-50.0%
Q2 2025Jul 31, 2025$-0.50$-0.38-31.6%
Next earningsThu, Jul 30·consensus EPS $-0.55

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.71$-42.6M
Q4 FY25$0———$-0.51$-41.9M
Q3 FY25$0———$-0.78$-29.6M
Q2 FY25$0———$-0.50$-29.6M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.22-$2.46 – -$2.050
FY27$34.8M$34.8M – $34.8M-$1.60-$2.42 – -$1.139
FY28$231.4M$231.4M – $231.4M-$0.69-$2.43 – $2.9013
FY29$571.3M$571.3M – $571.3M$1.25$1.25 – $1.2512
FY30$961.7M$961.7M – $961.7M$3.34$3.34 – $3.346

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+43.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+126.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 107.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.215-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 25Mark SullivanChief Legal Officer13.0K sh$586KSellJun 25Matthew T. WileyChief Commercial Officer2.9K sh$129KSellJun 25Brandi RobertsCFO3.0K sh$136KSellJun 25Robert BarrowCEO29.2K sh$1.3MSellJun 25Daniel KarlinChief Medical Officer10.0K sh$452KSellMar 25Robert BarrowCEO24.4K sh$451KSellMar 25Mark SullivanChief Legal Officer10.7K sh$198KSellMar 25Daniel KarlinChief Medical Officer8.0K sh$148K
+ 17 other (17 awards) in window

See when $DFTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

Definium Therapeutics entered an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00/share (prior close $36.18). The underwriter greenshoe of 3,088,235 shares was exercised in full on June 24, 2026. Gross proceeds including greenshoe are ~$805M; net proceeds ~$758M, earmarked for R&D, potential commercialization of DT120 ODT, and working capital. Material — a major capital raise at a ~6% discount to market; significant dilution for existing shareholders.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

Definium Therapeutics filed a 424B5 prospectus supplement on June 23, 2026 for an offering of 20,588,236 common shares at $34.00/share, with a 3,088,235-share overallotment option. Gross proceeds of ~$700M base ($805M with full greenshoe); underwriting discounts of ~$40.3M base ($46.3M with greenshoe). Bookrunners: J.P. Morgan, Jefferies, Leerink Partners, BofA Securities. Material dilution event — confirms pricing and terms of the large equity raise at a discount to market.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

Definium Therapeutics, Inc. filed a preliminary 424B5 prospectus supplement for a $500M public offering of common shares and pre-funded warrants (plus a $75M overallotment option), with shares last trading at $24.48 on June 18, 2026 and per-share pricing still to be determined. Bookrunners include J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities. A large, immediately dilutive raise for an emerging growth therapeutics company, appearing concurrent with positive Phase 3 MDD data.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Definium Therapeutics, Inc. announced positive topline data on June 22, 2026 from its Phase 3 'Emerge' study of DT120 ODT (oral dissolving tablet) for the treatment of major depressive disorder, simultaneously posting a data presentation on its website. Specific efficacy metrics (primary endpoint results, p-values, effect size) are in the attached press release (Exhibit 99.1) and presentation (Exhibit 99.2). Positive Phase 3 MDD data is a highly material, potentially transformative clinical milestone signaling regulatory submission eligibility, concurrent with Definium's $500M equity raise.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Definium Therapeutics, Inc. held its 2026 Annual General and Special Meeting on June 11, 2026. Shareholders approved an amendment to the 2025 Equity Incentive Plan adding 5,000,000 common shares for issuance; director elections and other standard proposals also passed. The 5M share plan expansion is the material disclosure — a meaningful dilution event for a small therapeutics company, reflecting typical early-stage equity compensation requirements.

3New insider — initial holdingsJan 293
8-KOfficer or director changeJan 298-K — Item 5.02: Officer or director change
+ 15 other (5 13Gs · 3 routine 8-Ks · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiologybusinesswire.com·4d agoWall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Betzacks.com·6d agoNew Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)businesswire.com·6d agoDefinium Therapeutics Announces New Employee Inducement Grantsbusinesswire.com·13d agoA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Yearprnewswire.com·24d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$MRNA$ATAI$ALLO$AURA$IOVA
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport